- Home
- DFP vs LXRX Comparison
DFP vs LXRX Comparison
Compare DFP & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFP
- LXRX
- Stock Information
- Founded
- DFP 2013
- LXRX 1995
- Country
- DFP United States
- LXRX United States
- Employees
- DFP N/A
- LXRX N/A
- Industry
- DFP Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- DFP Finance
- LXRX Health Care
- Exchange
- DFP Nasdaq
- LXRX Nasdaq
- Market Cap
- DFP 436.6M
- LXRX 428.8M
- IPO Year
- DFP N/A
- LXRX 2000
- Fundamental
- Price
- DFP $21.25
- LXRX $1.13
- Analyst Decision
- DFP
- LXRX Buy
- Analyst Count
- DFP 0
- LXRX 5
- Target Price
- DFP N/A
- LXRX $3.23
- AVG Volume (30 Days)
- DFP 56.2K
- LXRX 1.8M
- Earning Date
- DFP 01-01-0001
- LXRX 08-06-2025
- Dividend Yield
- DFP 6.73%
- LXRX N/A
- EPS Growth
- DFP N/A
- LXRX N/A
- EPS
- DFP N/A
- LXRX N/A
- Revenue
- DFP N/A
- LXRX $58,432,000.00
- Revenue This Year
- DFP N/A
- LXRX N/A
- Revenue Next Year
- DFP N/A
- LXRX N/A
- P/E Ratio
- DFP N/A
- LXRX N/A
- Revenue Growth
- DFP N/A
- LXRX 1504.83
- 52 Week Low
- DFP $15.45
- LXRX $0.28
- 52 Week High
- DFP $19.31
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- DFP 70.11
- LXRX 52.32
- Support Level
- DFP $20.77
- LXRX $1.03
- Resistance Level
- DFP $21.35
- LXRX $1.11
- Average True Range (ATR)
- DFP 0.16
- LXRX 0.06
- MACD
- DFP 0.04
- LXRX -0.01
- Stochastic Oscillator
- DFP 84.56
- LXRX 50.00
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.